The novel, highly-sensitive and non-destructive method for the quantification of the osteogenic potential of bone marrow mesenchymal stem cells (BM-MSCs), by the evaluation of its hydroxyapatite (HA), in vitro is 99mTc-HDP-Labelling. 99mTc-HDP (tracer) binds rapidly to HA and this uptake can be visualized and quantified. This study was performed to evaluate if this method is suitable to perform a real-time assessment during an ongoing cell culture and if the radioactive tracer may influence the cells and their ability to differentiate.

BM-MSCs (n=3) were cultivated in 35mm-dishes. Groups 1 and 3 received DMEM-LG based osteogenic media while Groups 2 und 4 were non-osteogenic controls.

Groups 1 and 2 (multi-labelling) were incubated with 5 MBq 99mTc-HDP for 30min on day 7 (d7) and the bound activity was measured using an activimeter. Subsequently the cell-culture was continued and again labelled with 99mTc-HDP on day 14 and 21 (d14, d21).

Groups 3 and 4 (single labelling), cultivation of the respective triplicates, ended on day 7, 14 and 21 (d7, d14, d21) followed by 99mTc-HDP-Labelling.

Statistical analysis using one-factor ANOVA (p<0.05).

Absolute tracer uptake increased steadily in both osteogenic groups: 1 (d7: 0.315; d14: 1.093; d21: 3.283 MBq) and 3 (d7: 0.208; d14: 0.822; d: 212.437 MBq) and was significantly higher than in the corresponding non-osteogenic control-group (Group 2 and 4) at all timepoints. (p<0.001).

No significant negative effect of the radioactive tracer could be revealed in group 1 (multi radioactive labelling on d7, d14, d21) compared to Group 3 (singe labelling).

The 99mTc-Uptake of groups 2 and 4 was not significantly different at any time.

Our data show that the repeated exposition to 99mTc-HDP has no negative influence on the osteogenic differentiation potential of BM-MSCs. Therefore, the method is capable of determining the amount of HA during an ongoing cell culture.

Methods

Between 2005 and 2012, 50 patients (23 female, 27 male) with nonunion of the humeral shaft were included in this retrospective study. The mean age was 51.3 years (14 to 88). The patients had a mean of 1.5 prior operations (sd 1.2;1 to 8).

All patients were assessed according to a specific risk score in order to devise an optimal and individual therapy plan consistent with the Diamond Concept. In 32 cases (64%), a change in the osteosynthesis to an angular stable locking compression plate was performed. According to the individual risk an additional bone graft and/or bone morphogenetic protein-7 (BMP-7) were applied.

Introduction: Different grafting materials for the filling of large bony defects are used in clinic. Aim of the present study was the comparative analyses of different bony grafting materials concerning their growth factor composition and osteoinductivity in vitro.

Materials & Methods: Different allograft preparations from the tissue bank of the Charité and two commercial demineralized bone matrices (DBM; DBX putty and Allomatrix) were analyzed. Using ELISA-kits following growth factors were quantified: VEGF, IGF-I, FGFa/b, TGF-β1, BMP-2/4, PDGF. Osteoinductivity was investigated by the induction of alkaline phosphatase activity in C2C12-cells.

Results: BMP-2 had the highest quantity within the different materials without differences between the materials. Differences in the quantity of the other growth factors were found between the investigated materials but also a high variability between the different batches was observable. The investigated materials showed individual differences which are donor related concerning their osteoinductive potential. A significant enhancement of osteogenic differentiation (AP) was seen for the two commercial DBM-products. For PES processed spongiosa from the tissue bank, 2 of the 5 materials had a negative effect on the AP-activity in the first incubation period but no effect in the second incubation period.

Discussion: The results of the present study revealed, that the different investigated grafting materials contain growth factors important for bone regeneration and an osteoinductive potential of the DBMs. A high batch/donor related variability, however, was detectable in both analysis. Important for the use in vivo is beside the osteoinductivity also the osteoconductivity and further comparative studies are necessary.

Despite biomechanical well established implants and improved operation techniques we still have a too high rate of complications in orthopaedic and trauma surgery like non-union, implant loosening or implant associated infections. The development of bioactive implants could improve the clinical outcome.

Growth factors are important regulators of bone metabolism. During fracture healing many growth factors or cytokines were locally released at the facture site. In several studies, different growth factors demonstrated osteoinductive and fracture stimulating properties.

In vitro and in vivo studies showed a stimulating effect of Insulin-like growth factor-I (IGF-I), Transforming growth factor-A71 (TGF-A71) and Bone morphogenetic protein-2 (BMP-2) on osteo- and chondrogenetic cells. The exact effectiveness and the interaction of these growth factors during fracture healing is not known so far. Further, the local application of these factors for therapeutically use in fracture treatment is still a problem.

A biodegradable poly(D,L-lactide)-coating of implants allows the local and controlled release of incorporated growth factors directly at the fracture site. The coated implant serves on the one hand for fracture stabilization and on the other hand as a drug delivery system. The coating has a high mechanical stability. The incorporated growths factors remain biologically active in the coating and were released in a sustained and controlled manner.

To investigate the effect of locally released growth factors IGF-I, TGF-A71 and BMP-2 and the carrier PDLLA on fracture healing, standardised closed fracture models were developed with a close relationship to clinical situation. Further, possible local and systemic side effects were analysed.

The results demonstrated a significantly higher stimulating effect of IGF-I on fracture healing compared to TGF-A71. The combined application of both growth factors showed a synergistic effect on the mechanical stability and callus remodeling compared to single treatment.

The local release of BMP-2 also enhanced fracture healing significantly – comparable to combination of IGF-I and TGF-A71. However, a higher rate of mineralisation was measurable outside the fracture region using BMP-2 in a rat fracture model.

Using a large animal model on pigs with a 1 mm osteotomy gap, the effectiveness of locally released growths factors could be confirmed. Further, the PDLLA-coating without any incorporated growth factors demonstrated a significantly effect on healing processes in both models. These investigations showed, that the local release of growth factors from PDLLA coated implants significantly stimulate fracture healing without any local or systemic side effects.

Comparing systemic with local stimulation techniques, we found an improvement of fracture healing by systemic administration of growth hormone and local application of IGF-I and TGF-A71. However, the combined use of both simulation techniques did not lead to a further increase of healing processes.

Investigations on the effectiveness and the interaction of growth factors during fracture healing demonstrated an dramatic effect in the early phases of healing processes. The growth factors stimulate the differentiation of osteoblasts with a higher production of collagen I in vitro and increase osteogenesis and vascularisation of the fracture callus in vivo.

Further applications of the coating technology are the use of PDLLA and growth factor coated cages for the stimulation of intervertebral fusion and the use of PDLLA and Gentamicin coated implants in order to prevent implant associated infections.

The first patients with open tibia fractures were treated with PDLLA and Gentamicin coated IM nails.